Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease

A technology for colchicine and liver disease, applied in the field of compound preparations, can solve problems such as no research proof

Inactive Publication Date: 2021-05-14
艾斯生物医药株式会社
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In this regard, although various attempts have been made on liver disease therapeutic agents including colchicine and hepatoprotective agents, no studies have yet demonstrated that even a small amount of compound preparations containing colchicine or hepatoprotective agents in combination can promote curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease
  • Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease
  • Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Embodiment 1. Experimental preparation and experimental method

[0078] 1-1. Preparation of experimental animals

[0079] Male Wistar rats [about 150g, 4-5 weeks old].

[0080] 1-2. Drugs and dosing schedule

[0081] The administration plan of carbon tetrachloride (CCl4) and colchicine (Colchicine) used in this experiment is as follows:

[0082] 1. Carbon tetrachloride: intraperitoneal administration of 0.4g / kg bw, 3 times a week, continuous administration for 10 weeks.

[0083] 2. Colchicine: 10, 50, 100 μg / kg bw orally, once a day, for 10 weeks.

[0084] 1-3. Classification of experimental groups

[0085] For the purpose of this experiment, the groups were classified as follows, with 12 animals in each group.

[0086] 1. Control group (distilled water administration group).

[0087]2. Vehicle administration group (only CCl4 solvent olive oil administration group).

[0088] 3. CCl4 administration group [0.4g / kg].

[0089] 4. CCl4 + colchicine [10 μg / kg].

[...

Embodiment 2

[0095] Example 2. Confirm the improvement of the curative effect of colchicine (Colchicine) on liver fibrosis under different dosages

[0096] 2-1. Quantification of hydroxyproline detection

[0097] Hydroxyproline was detected in each group to confirm the cumulative value of cellulose in the liver.

[0098] 【Table 1】

[0099] test group Hydroxyproline [μg / g liver] Normal 274.81±17.49 Vehicle 247.86±23.10 CCl4[0.4g / kg] 336.36±18.82 CCl4+ colchicine [10μg / kg] 320.12±13.32 CCl4+ colchicine [50μg / kg] 313.33±12.50 CCl4+ colchicine [100μg / kg] 302.25±10.25

[0100] As shown in Table 1, CC14-induced hepatic fibrosis exhibited a cellulose-reducing effect in the colchicine-administered group.

Embodiment 3

[0101] Embodiment 3. Experimental preparation and experimental method

[0102] 3-1. Preparation of experimental animals

[0103] Male Wistar rats [about 150g, 4-5 weeks old].

[0104] 3-2. Drugs and dosing schedule

[0105] The dosing schedule of carbon tetrachloride (CCl4), silymarin (Silymarin), colchicine (Colchicine) and dimethyl biphenyl dicarboxylate (DDB) used in this experiment is as follows:

[0106] 1. Carbon tetrachloride: intraperitoneal administration of 0.4g / kg·bw, 3 times a week, continuous administration for 10 weeks.

[0107] 2. Silymarin: Oral administration of 10, 30, 50 mg / kg·bw, once a day, for 10 consecutive weeks.

[0108] 3. Colchicine: Oral administration of 10 μg / kg bw, once a day, for 10 consecutive weeks.

[0109] 4. Dimethyl diphenylcarboxylate (DDB): Oral administration of 10, 20, 25 mg / kg·bw, once a day, for 10 consecutive weeks.

[0110] 5. UDCA: Oral administration of 30mg / kg·bw, once a day, continuous administration for 10 weeks.

[01...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a combination preparation for treating or enhancing a therapeutic effect on liver disease, and more particularly to a pharmaceutical composition for treating or enhancing a therapeutic effect on liver disease, which may be administered as a combination preparation prepared by combining colchicine and a conventional drug known to have an effect of protecting liver (biphenyl dimethyl dicarboxylate, silymarin, ursodeoxycholic acid, etc.), or in a combination type. The composition according to the present invention is a pharmaceutical composition for treating or enhancing a therapeutic effect on liver disease containing colchicine, which may be administered as a single dosage form of complex preparation with the liver protection preparation or in a combination type of individual dosage forms, and thus may be valuably used as a pharmaceutical composition for treating or enhancing a therapeutic effect on inflammable liver disease including liver fibrosis, liver cirrhosis, liver cancer or hepatitis.

Description

technical field [0001] The invention relates to a compound preparation for treating liver disease or promoting curative effect. The compound preparation takes colchicine as the main active ingredient and can be combined with one or more of DDB, silicon dioxide and UDCA according to the degree of liver disease. ingredients are prepared. Specifically, a pharmaceutical composition for promoting the curative effect of liver diseases prepared after specifically limiting the content of the above-mentioned drugs, the above-mentioned drugs (dimethyl biphenyl dicarboxylate, silymarin, ursodeoxychol acid, etc.) and colchicine as a compound preparation or in combination, the best pharmacological effects can be achieved. Background technique [0002] The liver is a biological organ that plays a central role in the metabolism of substances from the outside and in the body and continuously undergoes enzymatic reactions and energy metabolism. In fact, hepatitis, liver cirrhosis, and live...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/165A61K31/235A61P1/16A61P31/14A61P31/20A61P37/02A61P35/00
CPCA61K31/165A61K31/235A61K45/06A61P1/16A61P31/14A61P31/20A61P35/00A61P37/02A61K2300/00A61K31/194A61K31/357A61K31/51A61K31/525A61K31/575
Inventor 车旺祚
Owner 艾斯生物医药株式会社
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com